Currently, DS-8201a is being developed in two phase 3 confirmatory clinical trials for the treatment of patients with progressive unresectable or metastatic HER2+ breast cancer (DESTINY-Breast02 [NCT03523585] and DESTINY-Breast03 [NCT03529110], respectively). The gene discussed is ERBB2; the disease is breast cancer.